. Author manuscript; available in PMC: 2020 Nov 1.

Published in final edited form as: Curr Opin Rheumatol. 2019 Nov;31(6):595–602. doi: 10.1097/BOR.0000000000000656

Table 3.

Studies showing predictive significance of circulating Krebs von den Lungen-6 or chemokine ligand 18

KL-6

Reference	Population	Summary of findings

Kuwana et al. [35]	Nippon University	Predictive of ESLD development
Salazar et al. [36^∎]	GENISOS (US, Texas)	Predictive of worse FVC decline in 12 months
Sumida et al. [39]	Tokyo University	Predictive of lower DLCO
Volkmann et al. [38^∎]	SLSII (US, multicenter clinical trial)	Predictive of worse FVC decline in 12 months

CCL-18 (PARC)

Reference	Population	Summary of findings

Tiev et al. [40]	French cohort	Predictive of ILD event
Elhaj et al. [41]	GENISOS (US, Texas)	Predictive of worse FVC in 12 months
Hoffmann-Vold et al. [42]	Norwegian cohort	Annual decline in FVC
Elhai et al. [37^∎]	French/Norwegian cohort	Predictive of 10% decline in FVC
Volkmann et al. [38^∎]	SLSII (US, multicenter clinical trial)	Predictive of worse FVC decline in 12 months

CCL-18, chemokine ligand 18; DLCO, diffusion capacity of the lungs for carbon monoxide; ESLD, end-stage lung disease; FVC, forced vital capacity; ILD, interstitial lung disease; KL-6, Krebs von den Lungen-6; PARC, pulmonary and activation-regulated cytokine; SLS, scleroderma lung study.